Primecap Management Co. CA Lowers Stock Position in Waters Co. (NYSE:WAT)

Primecap Management Co. CA decreased its position in Waters Co. (NYSE:WATFree Report) by 5.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,259 shares of the medical instruments supplier’s stock after selling 5,400 shares during the period. Primecap Management Co. CA owned about 0.16% of Waters worth $30,374,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Exchange Traded Concepts LLC purchased a new position in Waters during the fourth quarter valued at $35,000. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Waters during the 3rd quarter worth approximately $33,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Waters in the fourth quarter valued at approximately $39,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Waters during the 4th quarter worth $41,000. Finally, VisionPoint Advisory Group LLC raised its position in shares of Waters by 300.0% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 108 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Stock Down 0.1 %

Shares of NYSE:WAT traded down $0.33 during trading on Friday, hitting $336.46. The company’s stock had a trading volume of 458,674 shares, compared to its average volume of 488,843. Waters Co. has a fifty-two week low of $231.90 and a fifty-two week high of $367.21. The business has a 50 day moving average price of $333.09 and a two-hundred day moving average price of $319.45. The company has a debt-to-equity ratio of 1.60, a quick ratio of 1.30 and a current ratio of 1.94. The company has a market capitalization of $19.96 billion, a PE ratio of 33.02, a P/E/G ratio of 5.35 and a beta of 0.98.

Waters (NYSE:WATGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.10 by $0.11. The company had revenue of $636.80 million during the quarter, compared to the consensus estimate of $635.57 million. Waters had a net margin of 20.75% and a return on equity of 66.59%. Waters’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.49 EPS. As a group, research analysts expect that Waters Co. will post 11.86 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on WAT. Stifel Nicolaus lifted their price objective on Waters from $330.00 to $332.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Barclays reduced their target price on shares of Waters from $300.00 to $295.00 and set an “underweight” rating on the stock in a research note on Wednesday, May 8th. TD Cowen lifted their target price on Waters from $350.00 to $358.00 and gave the company a “hold” rating in a research report on Wednesday, May 8th. Evercore ISI boosted their price objective on shares of Waters from $320.00 to $340.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, Robert W. Baird lowered their target price on shares of Waters from $319.00 to $312.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating and ten have assigned a hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $305.78.

Check Out Our Latest Research Report on Waters

Insider Activity

In other Waters news, Director Linda Baddour sold 500 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $355.54, for a total value of $177,770.00. Following the completion of the sale, the director now owns 2,250 shares of the company’s stock, valued at $799,965. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Christopher A. Kuebler sold 4,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $361.64, for a total value of $1,446,560.00. Following the completion of the transaction, the director now directly owns 14,716 shares of the company’s stock, valued at $5,321,894.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Linda Baddour sold 500 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $355.54, for a total value of $177,770.00. Following the sale, the director now directly owns 2,250 shares in the company, valued at approximately $799,965. The disclosure for this sale can be found here. Insiders own 0.82% of the company’s stock.

Waters Profile

(Free Report)

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

See Also

Institutional Ownership by Quarter for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.